Stemedica licenses stem cells to Kalbe Farma

04/26/2013 | Genetic Engineering & Biotechnology News

Stem Cell and Cancer Institute, a unit of PT Kalbe Farma, secured exclusive licensing rights to Stemedica Asia's ischemic-tolerant adult allogeneic mesenchymal and neural stem cells for use in clinical research in the Philippines, Thailand and Indonesia. The deal could be extended to additional countries in Asia.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
OR
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Counsel I – Clinical Contracts
Gilead Sciences
Foster City, CA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Vice President, Idaho Regional Director
PacificSource
Boise, ID